两试两败！阳光诺和收购朗研生命再折戟

Group 1 - The core point of the article is that Sunshine Nuohuo (688621) has terminated its acquisition of Jiangsu Langyan Life Science Technology Co., Ltd. (Langyan Life) due to changes in the market environment, marking the second failed attempt to acquire the company since 2022 [1][5][4] - The termination announcement was made on January 28, where the company decided to withdraw its application for the asset purchase and authorized management to handle the termination matters [3][4] - The acquisition was initially planned to be financed through the issuance of shares and convertible bonds, with the aim of enhancing the pharmaceutical industrial segment and achieving a "CRO + pharmaceutical industry" layout [3][5] Group 2 - Sunshine Nuohuo's previous attempt to acquire Langyan Life in October 2022 also ended in failure, with the company citing significant changes in the market environment as the reason for termination [5][6] - Financial data indicates that Langyan Life's revenue fluctuated, with reported revenues of approximately 510 million yuan and 617 million yuan for 2021 and 2022, respectively, and projected revenues of 463 million yuan, 415 million yuan, and 231 million yuan for 2023, 2024, and the first half of 2025 [5][6] - The company faced challenges in responding to the Shanghai Stock Exchange's inquiry regarding the acquisition, ultimately leading to the decision to terminate the transaction rather than provide a response [8][9]